GlassScriptPhysician profile
Alison Marie Granier
NPI 1669709143
$4,462.73
in general payments reported to CMS, 2019-2025
18 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $13.96 · 2021: $195 · 2022: $766 · 2023: $2,849 · 2024: $227 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,269 · Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,268.78 |
| Food and Beverage | $1,006.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,071.14 | 2022-2023 | Gsw-Istentinjectwtrabecular Micro-Bypass System, Istent Inject Trabecular Micro-Bypass System, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $342.66 | 2019-2025 | Clareon, Tryptyr, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $306.30 | 2019-2024 | Eylea Hd |
| Astellas Pharma US INC | $148.31 | 2023-2024 | Izervay |
| Ivantis, INC | $147.31 | 2021 | |
| Genentech USA, INC. | $114.30 | 2022 | |
| Merz Pharmaceuticals, LLC | $62.65 | 2023-2024 | Xeomin |
| Dompe US, INC. | $46.31 | 2022-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $44.86 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $23.83 | 2025 | Miebo, Xiidra |
| Alimera Sciences, INC. | $23.83 | 2023 | Iluvien |
| Johnson & Johnson Surgical Vision, INC. | $21.24 | 2019 | |
| Rxsight INC | $21.16 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.08 | 2019 | |
| Biotissue Holdings INC. | $18.92 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $18.16 | 2022 | |
| Travere Therapeutics, INC. | $17.92 | 2022 | |
| Ani Pharmaceuticals, INC. | $13.75 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Granier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.